Generic Industry Specialization, Consolidation Driven By Rising Product Complexity
Executive Summary
The generic market is moving toward more complex products and formulations, which will separate companies based on capabilities, CEOs said at the Generic Pharmaceutical Association annual meeting.
You may also be interested in...
Entering The Generics Business In Mature Markets: Lessons Learned From 4,500 Launches
In response to major market challenges, Big Pharmas have or are considering entering the small-molecule generics business. An IMS Consulting Group analysis of more than 4,500 generics launches between 2005 and 2010 tracks key attributes would-be branded company players need to know for success.
Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.
Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.